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Abstract
Background: Inflammatory bowel disease (IBD) is a chronic complex disease of the gastrointestinal tract. Patients
with IBD can experience a wide range of symptoms, but the pathophysiological mechanisms that cause these
individual differences in clinical presentation remain largely unknown. In consequence, IBD is currently classified
into subtypes using clinical characteristics. If we are to develop a more targeted treatment approach, molecular
subtypes of IBD need to be discovered that can be used as new drug targets. To achieve this, we need multiple
layers of molecular data generated from the same IBD patients.
Construction and content: We initiated the 1000IBD project (https://1000ibd.org) to prospectively follow more
than 1000 IBD patients from the Northern provinces of the Netherlands. For these patients, we have collected a
uniquely large number of phenotypes and generated multi-omics profiles. To date, 1215 participants have been
enrolled in the project and enrolment is on-going. Phenotype data collected for these participants includes
information on dietary and environmental factors, drug responses and adverse drug events. Genome information
has been generated using genotyping (ImmunoChip, Global Screening Array and HumanExomeChip) and sequencing
(whole exome sequencing and targeted resequencing of IBD susceptibility loci), transcriptome information
generated using RNA-sequencing of intestinal biopsies and microbiome information generated using both
sequencing of the 16S rRNA gene and whole genome shotgun metagenomic sequencing.
Utility and discussion: All molecular data generated within the 1000IBD project will be shared on the European
Genome-Phenome Archive (https://ega-archive.org, accession no: EGAS00001002702). The first data release, detailed
in this announcement and released simultaneously with this publication, will contain basic phenotypes for 1215
participants, genotypes of 314 participants and gut microbiome data from stool samples (315 participants) and
biopsies (107 participants) generated by tag sequencing the 16S gene. Future releases will comprise many more
additional phenotypes and -omics data layers. 1000IBD data can be used by other researchers as a replication
cohort, a dataset to test new software tools, or a dataset for applying new statistical models.
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Conclusions: We report on the establishment and future development of the 1000IBD project: the first
comprehensive multi-omics dataset aimed at discovering IBD biomarker profiles and treatment targets.
Keywords: Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Genome, Microbiome, Transcriptome,
Dataset
Background
Inflammatory bowel disease (IBD), comprising Crohn’s
disease (CD) and ulcerative colitis (UC), is a chronic
complex disease of the gastrointestinal (GI) tract. IBD is
very heterogeneous: disease location within the GI tract,
disease behaviour, and average disease activity can vary
greatly between patients [1]. Thus far, large numbers of
individual genetic variants, environmental factors and gut
microbes have been discovered that associate with the on-
set of IBD [1–9]. However, it remains largely unknown
how pathophysiological changes in specific pathways lead
to different clinical subphenotypes of IBD, and which
treatment could best be applied.
Given our current lack of understanding of these patho-
physiological pathways, patients with IBD are classified
into subtypes using only clinical characteristics. The classi-
fication tool currently in use is the Montreal classification,
which consists of age of onset (A), disease location (L), and
disease behaviour (B) for CD and age of onset (A), disease
extent (E), and disease severity (S) for UC [10]. A combin-
ation of the Montreal classification and current disease ac-
tivity is used to determine a treatment regimen comprising
anti-inflammatory drugs and/or surgery.
Meanwhile, the number of new anti-inflammatory bio-
logical drugs targeting specific molecular pathways is ris-
ing rapidly. Currently, these new drugs are used when
regular anti-inflammatory drug treatment fails. However,
identifying IBD subtypes on the molecular pathway level
could enable a much more targeted treatment approach in
which the pathways affected in specific subtypes of IBD
could be targeted by specific monoclonal antibodies.
Multiple research groups and consortia throughout
the world are generating datasets combining clinical data
with either genome data, transcriptome data, or gut
microbiome data. By studying these datasets, researchers
can answer important individual questions. However, an
integrated effort is required if we are to meet the key
objectives needed to pursue targeted treatment:
1. To discover molecular subtypes of IBD and match
available monoclonal antibody treatment to these
subtypes.
2. To discover biomarker profiles that capture the clinical
heterogeneity of IBD and can be used as predictors.
3. To discover and prioritise the best new targets for
early-stage drug discovery.
Meeting these objectives requires the assessment and
integration of different layers of -omics information, sup-
plemented with high-resolution phenotype data in the
same IBD patients. Important IBD multi-omics projects
already exist in the longitudinal integrative Human Micro-
biome Project [11] (iHMP or HMP2), the PRISM-cohort
[12], and the RISK-cohort [7] in the United States. Previ-
ous efforts from the RISK cohort, the PRISM cohort, and
samples from patients treated in our university hospital, as
well as from consortia in which these cohorts participate,
have already enabled the first steps towards precision
medicine in IBD. For example, the discovery of genetic
variants enables the prediction of the risk of pancreatitis
as a severe side-effect of azathioprine, a commonly used
immunosuppressant in IBD [13]. Microbial DNA profiles
and RNA-sequencing profiles from the intestinal biopsies
of the RISK cohort have uncovered RNA-microbe interac-
tions and shown that biopsies taken from the distal colon
can predict the IBD disease location higher up in the in-
testine [7, 14]. In addition, stool samples from the PRISM
cohort have also been used to discover microbial profiles
that can predict the efficacy of vedolizumab, a biological
drug regulating T-cell homing to the gut [15], while a
genetic variant in the WWOX gene discovered using ge-
notypes of IBD patients treated in our hospital can be
used to assess the risk of stricturing and penetrating
Crohn’s disease behavior [16].
We initiated the 1000IBD project to prospectively follow
more than 1000 IBD patients from the Northern prov-
inces of the Netherlands and collect a uniquely large num-
ber of phenotypes. Phenotype data include—but are not
limited to—information on dietary and environmental fac-
tors, drug responses and adverse drug events. In addition,
we will generate cross-sectional multi-omics layers.
Here, we report on the establishment and future de-
velopment of the 1000IBD project and release the first
data from the project. This first release and future
data releases will be stored externally in the European
Genome-phenome Archive (EGA) of the European
Bioinformatics Institute (EBI) and Centre for Genomic
Regulation [17]. This first 1000IBD data release includes
basic phenotypes of 1215 participants, host genotypes based
on the Immunochip for 314 participants, and gut micro-
biome data from 315 stool samples (one per participant)
and 107 biopsies (one per participant) generated by tag
sequencing the 16S rRNA gene.
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Construction and content
To create the 1000IBD dataset, we collected and gener-
ated extensive prospective phenotype, diet and environ-
ment data, extensive treatment response and adverse
treatment event data, and a multi-omics dataset of the
same patients.
1000IBD cohort, patient selection and recruitment
All IBD patients treated in the specialized IBD Center of
the Department of Gastroenterology and Hepatology of
the University Medical Center Groningen (UMCG) are
asked to participate in the 1000IBD project. Patients re-
cruited for the 1000IBD project include new patients
with new-onset IBD, new patients with existing IBD
newly referred to our hospital, and patients with IBD
already being treated in our hospital. Since there are
more than 2000 IBD patients already being treated in
our hospital, this last group is gradually being asked to
participate to allow our research nurses to obtain the
data and samples in an organized way. Since our univer-
sity hospital is a tertiary referral centre, the number of
new-onset IBD patients is limited.
The only inclusion criteria for the 1000IBD project are
that patients need to: (1) be at least 18 years old, (2) have
IBD based on accepted radiological, laboratory and
endoscopic findings, (3) have provided informed consent
and (4) able to speak, read and write Dutch in order to
be able to fill in the questionnaires. Paediatric patients
are not included in 1000IBD because our institutional
review board (IRB) approval does not cover them. There
are no additional inclusion or exclusion criteria. Inclu-
sion is still on-going, and the project had enrolled 1215
IBD patients as of September 1, 2017.
1000IBD informed consent and IRB approval
All patients are asked to sign an informed consent form.
Once they have given written informed consent, we collect,
generate and integrate clinical data, diet and environmental
data, genome data, transcriptome data, and microbiome
data for each participant. The 1000IBD project was ap-
proved by the UMCG IRB (IRB number 2008.338).
1000IBD: Logo
A 1000IBD logo depicting the intestine and the multifa-
ceted character of the project was created to represent
the project (Fig. 1).
1000IBD Datamodel and identifier
Every 1000IBD participant has a unique pseudo-anonymized
1000IBD-identifier that is used to link all clinical phenotypes
and molecular data layers. A model of the 1000IBD
dataset is depicted in Fig. 2.
Generation of clinical phenotype and treatment response
data
The collection of prospective data on clinical phenotypes,
treatment responses and adverse events is incorporated
into the regular IBD clinical care process in the outpatient
department of our IBD centre. These phenotype and treat-
ment data serve both as the electronic health record and
as a research dataset. This approach of collecting data ‘at
the source’, i.e. during the patient visit, has been recom-
mended by the Dutch Federation of University Medical
Centres (NFU) [18].
An extensive prospective phenotype data model was de-
veloped to ensure uniform data collection over time and
across different healthcare professionals. Data items and
descriptions of the data model are listed in Additional file 1:
Table S1. This phenotype model is similar to the phenotype
model of the Dutch IBD Biobank (part of Parelsnoer [19])
to which a subset of the 1000IBD phenotypes is automatic-
ally uploaded [20]. At inclusion, the research nurse fills in
most of the data items. The gastroenterologist subse-
quently only updates data items that have changed since
the last patient visit. Table 1 provides an overview of the
available data on the most important phenotypes and
summary statistics of the 1215 1000IBD participants.
Generation of dietary and environmental data
We developed two new questionnaires to gather dietary
and environmental data of IBD patients. 1000IBD partic-
ipants can fill out these questionnaires using a secure
web application.
The Groningen IBD-specific Food Frequency Question-
naire (GrIB FFQ) was designed to assess the current dietary
Fig. 1 1000IBD Project Logo. This logo depicts the intestine and the
multifaceted character of the project
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habits and nutritional intake of IBD patients. It consists
of 119 questions on food items that are grouped into
categories: breakfast, lunch, dinner, snacks and drinks.
Since IBD patients often follow unguided dietary habits,
i.e. those made without consulting a physician or diet-
ician first, population-specific and more extensive items
(e.g. dairy substitutes, meat replacers and supplements)
are included in the questionnaire. When using this nutri-
tional tool, patients report the intake of foods consumed
during the previous month. The food data obtained via
the GrIB FFQ will be converted into energy and nutrient
intake (in grams/day) using the NEVO food composition
database of 2016 (NEVO 2016, RIVM, Bilthoven, the
Netherlands). The nutritional intake part of the GrIB FFQ
was developed in collaboration with, and validated by, the
division of Human Nutrition of Wageningen University
using standardized procedures [21, 22].
The GrIB FFQ provides a broader overview than trad-
itional food questionnaires. It also assesses factors that in-
fluence nutrition expenditure but are often disregarded.
To complement the questions on nutritional intake, items
on patient’s conceptions about the role of nutrition in IBD
Fig. 2 Simplified 1000IBD data model. 1000IBD-ID is the 1000IBD identifier used in every data-layer, also referred to as primary key (PK) and
foreign key 1 (FK1). RNAseq: RNA-sequencing, 16S: Sequencing data of the microbial 16S rRNA gene; WGS: whole genome shotgun sequencing
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have been added. Since these additional items could not
be included in the standard validation procedure of the
Wageningen University, the entire GrIB FFQ will be vali-
dated with data collected in an upcoming randomized
controlled trial.
The Groningen IBD Environmental Questionnaire
(GIEQ) is designed to study the role of lifestyle and envir-
onment in the development and course of IBD. The GIEQ
includes a large number of factors that could potentially
influence disease risk and disease course such as mode of
birth (vaginal vs. caesarean), whether patients were breast-
fed, their living surroundings and sun exposure. In the
GIEQ, 1000IBD participants are also asked about differ-
ences in lifestyle before and after their IBD diagnosis to
see which lifestyle changes coincide with the onset of IBD.
The GIEQ has just been published and validated [23].
Generation of new molecular data and previously
generated data
Molecular data of multiple –omics layers is being gener-
ated during the 1000IBD project. However, the 1000IBD
cohort is comprised of both newly generated molecular
data and data that was previously generated from samples
from the same IBD patients. If informed consent was
given, all this data has been added to the 1000IBD project.
Generation of host genetic data
Host genomic data is generated in the 1000IBD project
using genotyping (Illumina ImmunoChip, Global Screening
Array, and the HumanExomeChip) and sequencing
(Pooled targeted re-sequencing and whole exome se-
quencing). Peripheral blood samples were drawn from
Table 1 Clinical phenotypes of 1215 1000IBD participants
No. of participants 1215
Age (Median ± IQR) 41 ± 25
Sex
Male (%) 510 (41.97)
Female (%) 705 (58.03)
Diagnosis
Crohn’s Disease (%) 615 (50.62)
Ulcerative Colitis (%) 495 (40.74)
IBDU (%) 61 (5.02)




A: Age of Onset
A1 (%) 159 (13.09)
A2 (%) 710 (58.44)
A3 (%) 253 (20.82)
L: Disease Location (CD only)
L1 (%) 224 (36.42)
L2 (%) 120 (19.51)
L3 (%) 255 (41.46)
L4 (%) 65 (10.57)
B: Disease Behaviour (CD only)
B1 (%) 301 (48.94)
B2 (%) 208 (33.82)
B3 (%) 102 (16.58)
Perianal 189 (30.73)
E: Disease Extent (UC only)
E1 (%) 57 (10.25)
E2 (%) 162 (29.13)
E3 (%) 299 (53.78)
S: Disease Severity (UC only)
S1 (%) 29 (5.22)
S2 (%) 139 (25.00)
S3 (%) 191 (34.35)
S4 (%) 119 (21.40)
Age at Diagnosis in years (Median ± IQR) 27 ± 19
Disease Duration at Recruitment in years (Median ± IQR) 8 ± 12
Medication Exposure
Steroids % 90.07
Steroids CD % 91.99
Steroids UC % 88.28
Steroids IBDU % 88.33
Immunosuppressors % 68.32
Immunosuppressors CD % 79.08
Immunosuppressors UC % 56.97
Table 1 Clinical phenotypes of 1215 1000IBD participants
(Continued)
Immunosuppressors IBDU % 56.67
Biologicals % 37.30
Biologicals CD % 55.07
Biologicals UC % 17.37
Biologicals IBDU % 25.00
Mesalazines % 44.34
Mesalazines CD % 18.06
Mesalazines UC % 70.99
Mesalazines IBDU % 83.33
Average Disease Activitya
HBI (Average ± Standard Deviation) 2.99 ± 3.18
SSCAI (Average ± Standard Deviation) 1.61 ± 1.97
aFor each patient, the median disease activity was determined. For the entire
group the average of the individual medians is presented here
IQR interquartile range, CD Crohn’s disease, UC ulcerative colitis, IBDU
inflammatory bowel disease undetermined, IBDI inflammatory bowel disease
intermediate, HBI Harvey-Bradshaw Index, SSCAI Simple Clinical Colitis
Activity Index
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1000IBD participants and DNA was isolated from
EDTA stabilized blood using either phenol-chloroform
or the Qiagen Autopure LS with Puregene chemistry
(Qiagen, USA), as previously described [24].
Genotyping using the ImmunoChip
Host DNA samples from 314 of the 1215 1000IBD partici-
pants was genotyped using the ImmunoChip [25] during
previous projects between 2010 and 2013 [3], and this data
has been added to the 1000IBD project. The ImmunoChip
is an Illumina Infinium array comprising 196,524 Single
Nucleotide Variants (SNVs) as well as a small number of
insertion and deletion markers. These SNVs and markers
were selected based on results from genome-wide associ-
ation studies of IBD and 11 other immune-mediated dis-
eases. Normalized intensities for all samples were called
using the OptiCall clustering program [26]. Marker and
sample quality control was performed as described previ-
ously [6]. Because the ImmunoChip is no longer available,
no additional DNA samples will be genotyped by this
method. Newer arrays such as the Global Screening Array
(GSA) will now be used to ensure that all 1000IBD partici-
pants are genotyped.
Genotyping using the GSA
At the moment, host DNA samples from 1013 of the
1215 1000IBD participants have been genotyped using
the Infinium GSA-24 v1.0 BeadChip combined with the
optional Multi-Disease drop-in panel (GSA-MD). The
GSA-MD array comprises a multi-ethnic genome-wide
backbone combined with Multi-Disease Drop-in con-
tent derived from exome sequencing and meta-analyses
of several phenotype-specific consortia including the
International IBD Genetics Consortium (IIBDGC). The
GSA-MD includes over 700,000 genetic variants. Geno-
types were called using the OptiCall [26] clustering
program (opticall.bitbucket.io) and quality control steps
were performed using PLINK 1.9 (www.cog-genomic-
s.org/plink/1.9/) [27]. The remaining 1000IBD partici-
pants, as well as future 1000IBD participants, will also
be genotyped using the GSA.
Genotyping using the Illumina HumanExomeChip
DNA samples of 419 CD patients were genotyped using
the Illumina HumanExome-12 v1.1 BeadChip array, which
contains 242,901 exonic genetic variants, the majority
being low-frequency or rare non-synonymous, splice,
or stop-altering variants. The remaining 1000IBD par-
ticipants will not be genotyped using the HumanExo-
meChip, but will instead be sequenced using Whole
Exome Sequencing.
Pooled targeted re-sequencing of UC patients
Host DNA samples of pooled targeted deep high-throughput
sequencing has been performed of 122 UC-associated genes
[28]. Pooled targeted enrichment of DNA from 404 1000IBD
participants (12 individuals per pool) was performed
using a custom-made kit (Agilent HaloPlex, designed
with Agilent’s Sure Design), resulting in coverage of
99.9% of the target sequence. After enrichment, se-
quencing was performed on the Illumina HiSeq 2500.
Whole exome sequencing
Host DNA samples from 1003 1000IBD participants
were whole exome sequenced according to the Broad
Institute of Harvard and MIT Standard Human Whole
Exome Sequencing v5 (http://genomics.broadinstitute.org/
products/whole-exome-sequencing). DNA samples were
processed using the Illumina Nextera preparation kit
and hybrid capture was performed using Illumina Rapid
Capture Enrichment (37Mb target). Sequencing was done
on the Illumina HiSeq platform to generate 150 bp paired
DNA reads. Exome sequencing reads were subsequently
processed in accordance with the Broad Institute of
Harvard and MIT best practice guidelines (https://soft-
ware.broadinstitute.org/gatk/best-practices/). Reads were
mapped to the human genome reference sequence build
37 using BWA MEM5. The Genome Analysis Toolkit
(GATK) [29] version 26 was used to call alleles at variant
sites as previously described [30]. The VQSR pipeline was
used to assess the quality of called variants.
Intestinal biopsies and the generation of transcriptome
data
Intestinal biopsies were collected from 1000IBD partici-
pants during colonoscopies for regular clinical care.
These biopsies were immediately snap-frozen by the
endoscopy nurse or research technician present during
the endoscopy procedure using liquid nitrogen, which is
readily available in the endoscopy room. We were able
to successfully isolate both DNA and RNA from the
snap-frozen samples, and results using the bacterial
DNA from biopsies have already been published [31]. To
date, 5933 biopsies from 900 patients have been snap
frozen in liquid nitrogen and stored at − 80 °C. DNA and
RNA were simultaneously isolated from 300 fresh frozen
human intestine biopsies using the AllPrep DNA/RNA
Mini kit (Qiagen, REF no: 80204) according to the com-
pany’s protocol. Biopsies were homogenized in RLT plus
buffer containing β-mercaptoethanol using the Qiagen
Tissue Lyser with stainless steel beads (5 mm mean
diameter, Qiagen REF nr: 69989). Sample preparation
was executed using the BioScientific NextFlex mRNA
sample preparation kit. Sequencing was performed on
the Illumina NextSeq500 sequencer. The RNA samples
were pseudo-randomized on plates to assure that no
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single factor was dominant on one plate (IBD diagnosis,
disease location or disease activity). RNA-sequencing was
conducted in two batches comprising one pilot batch of
one plate of 20 samples, and one batch of one plate of 80
samples and two plates containing 100 samples each.
When a principal coordinate analysis was executed as part
of the QC, no relevant batch effect was detected. The 300
samples generated 20 million reads per sample.
Generation of gut microbiome data
To date, stool samples have been collected from 544
participants of 1000IBD. Participants were asked to
freeze a stool sample within 15min of stool production
at home. A medical student or research nurse visited
each participant at home shortly after production to col-
lect the sample on dry ice for transport to the laboratory
at -80 °C. We surveyed 248 IBD patients who took part
in the stool sampling. Of these 248 patients, only 3 re-
quired more than 15min to store their faecal sample in
their freezer and 13 did not fill in this particular ques-
tion. (Bolte et al. Submitted).
In the laboratory, microbial DNA was isolated using the
Qiagen AllPrep DNA/RNA Mini Kit cat. # 80204 with the
addition of mechanical lysis, as previously described [7]. The
microbial DNA samples were randomized on 96-well plates
so that age and IBD diagnosis were mixed. The plates con-
taining microbial DNA were sent to the Broad Institute, Bos-
ton, USA for 16S sequencing in one batch. These microbial
DNA samples were stored at the Broad Institute at -80 °C,
and whole genome metagenomic sequencing was performed
at a later stage. A second batch of microbial DNA was sent
to the Broad Institute for whole genome shotgun metage-
nomic sequencing using the same procedure. When a prin-
cipal coordinate analysis (PCA) was executed as part of the
QC, no relevant batch effects were detected.
16S rRNA gene tag sequencing data
The hyper-variable region V4 of the 16S rRNA gene of
microbial DNA of 315 stool samples from 315 1000IBD
participants and 107 intestinal biopsies of 107 1000IBD
participants was sequenced using the Illumina MiSeq.
After sequencing, custom scripts were used to remove
the primer sequences and align the paired end reads [7].
Shotgun metagenomic sequencing data from stool samples
Microbial DNA of 544 stool samples from 544 1000IBD
participants was whole genome shotgun sequenced
using the Illumina HiSeq platform. Basic QC was per-
formed by the sequencing facility using an in-house
pipeline to remove low quality reads from the raw
metagenomic sequencing data. Samples with a read
depth less than 10 million reads were excluded. Next,
quality trimming and adapter removal was performed
using Trimmomatic (v.0.32) [32].
Future LONGITUDAL sampling of biomaterial
In addition to the current 1000IBD biomaterial collections,
subsets of the 1000IBD cohort will be sampled longitudin-
ally. In the IBD Tracker project, a selection of 1000IBD
participants will undergo weekly stool sampling. A separate
IRB approval has been obtained for this project.
Local infrastructure and software
Structured IBD-specific electronic health record
All clinical phenotype data from described in the in-
formation model (Additional file 1: Table S1) is col-
lected using an IBD-specific electronic health record
(IBD-EHR). This IBD-EHR is used in clinical care
and will, in time, be integrated into the new UMCG
hospital electronic health record system, EPIC
(http://www.epic.com).
Patient reported outcome measures using an online tool:
myIBDcoach
Some phenotypes are scored by the IBD patients them-
selves. To assist patients in scoring these patient-reported
outcome measures (PROMS), e.g. clinical disease activity,
a smartphone app and a web application called myIBD-
coach is used [33]. Gradually, more PROMS will be imple-
mented and added to the phenotype model.
Research data in MOLGENIS research
Once phenotype data is extracted from the IBD- EHR
and the myIBDCoach smartphone app, it is uploaded
into MOLGENIS Research, a web-based application that
automatically generates the summary statistics [34, 35].
Raw sequencing data stored on a high-performance
computer cluster
Raw sequencing data is stored on the Calculon high-per-
formance computer cluster of the UMCG.
Privacy and information security
The software and information infrastructure were built
taking into account Dutch NEN7510 [36] and international
ISO 27.001 [37] information security guidelines as much as
possible. A penetration test will soon be performed by the
UMCG IT department on https://1000IBD.org.
Utility and discussion
Use of 1000IBD data
The data of the 1000IBD project has already led to a num-
ber of important discoveries. The Immunochip genotypes
were used to unravel the host genetic landscape of IBD as
part of the IBD Genetics Consortium effort [2, 3, 6]. The
UC pooled targeted resequencing study lead to the discov-
ery of a novel UC-associated variant [28]. The gut micro-
biome data was used to detect the microbial composition
of the gut in IBD patients [8]. Phenotype, genotype and gut
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microbiome data were integrated to look at the complex
relations between these different data layers [8, 31].
The 1000IBD data is a versatile resource. Researchers
investigating IBD can use the data as a replication
cohort or as a pilot cohort to test new hypotheses. Soft-
ware developers can use the data to test new tools, for
example those built to analyse the genome or the gut
microbiome. Mathematicians and statisticians can apply
new statistical models to the data. A major advantage of
the 1000IBD data for all these researchers is that they
will not have the considerable cost of building a cohort
or of generating genotype, whole exome, transcriptome
and gut microbiome data.
Sharing 1000IBD data in releases
The 1000IBD data will be made available in three stages
(Fig. 3). In Stage 1, data that has been generated or will
be generated is announced. In Stage 2, summary statis-
tics will be made available. In Stage 3, the data itself will
be publicly released. In the end, all data that does not
violate patient privacy regulations will be made publicly
available.
Data release 1
The first release of 1000IBD contains the basic phenotypes
of 1215 participants, Immunochip genotypes of 314 par-
ticipants and gut microbiome data of 315 participants.
The content of the data release 1 is presented in Table 2.
Finding and exploring 1000IBD data
The 1000IBD Project can be found in the European
Genome-Phenome Archive https://ega-archive.org/stud-
ies/EGAS00001002702, and will be added to the local
research data catalogue of the UMCG and the University
of Groningen, the national biomedical research data
catalogue BBMRI-NL (Biobanking and BioMolecular
resources Research Infrastructure The Netherlands)
(www.bbmri.nl) and the European biomedical research
data catalogue BBMRI-ERIC [38] (Biobanking And
BioMolecular Resources Research Infrastructure - Euro-
pean Research Infrastructure Consortium). The 1000IBD
data can be explored online on our website: https://
1000IBD.org. Here, summary statistics of the phenotypes
of 1000IBD participants for the entire cohort and for the
subsets of participants for whom omics data is available
can be viewed.
Fig. 3 Flow of research data from the 1000IBD project. In Stage 1, data that has been generated or will be generated is announced. In Stage 2,
summary statistics will be made available. In Stage 3, the data itself will be publicly released
Table 2 Content of Data release 1. Released on June 5th, 2018









o A: Age of onset
o L: Disease location (CD only)
o B: Disease behaviour (CD only)
o E: Disease extent (UC only)
o S: Disease severity (UC only)
1215 of 1215 participants of 1000IBD
-omics data available from
557 of the 1215 participants of 1000IBD
TSV (Tab-separated file)
Genome
-Immunochip genotypes 314 of 1215 participants of 1000IBD IDAT
Microbiome
-16S rRNA gene sequences from stool samples 315 of 1215 participants of 1000IBD FASTQ
Microbiome
-16S rRNA gene sequences from biopsies 107 of 1215 participants of 1000IBD FASTQ
Microbiome
-Whole genome shotgun metagenomics sequences from stool samples 355 of 1215 participants of 1000IBD FASTQ
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Downloading 1000IBD research data
The 1000IBD research data can be downloaded from the
EGA at https://ega-archive.org using accession number
EGAS00001002702. All raw files (FASTQ, IDAT) from
genotyping and sequencing of the genome, transcrip-
tome and microbiome will be available to run through
custom pipelines.
Recalling 1000IBD participants for additional sampling
1000IBD participants are recallable for additional sampling.
The possibility to recall patients for additional material is
only available to UMCG researchers. However, collabora-
tions in which extra material is collected are possible.
Coauthorship and citing 1000IBD
The arrangements for publication regarding co-authorship
or just citation will depend on the extent of cooperation
required by the Groningen team. If IBD participants need
to be recalled for additional sampling or if large data
processing efforts by the Groningen team are required,
co-authorship will be required. However, if a limited
amount of data is requested from the EGA, citation of
the current manuscript would suffice.
Privacy and controlled access
To share the molecular and clinical data in a responsible
way, we need to maintain patient privacy. It is therefore
not possible to publicly share extensive phenotype data,
and the publicly available phenotype data will remain
limited to a basic phenotype set. 1000IBD data is stored
externally in the EGA, but because 1000IBD consists of
patient data, a controlled access procedure is in place.
Preparation of next release
While the first data is released, preparations for the second
data release are on-going. The second 1000IBD data re-
lease will consist of: i. the complete 544 microbiome WGS
metagenomes from stool samples from 544 1000IBD
participants and ii. pooled targeted resequencing of UC
susceptibility loci.
Conclusions
The 1000IBD project aims to discover molecular sub-
types of IBD and biomarker profiles that capture the
clinical heterogeneity of IBD and to prioritise new tar-
gets for early stage drug discovery or other interven-
tional strategies by generating extensive multi-omics and
phenotype data of over 1000 IBD patients. The project is
a showcase for FAIR data management following the
guiding principles for scientific data management and
stewardship (FAIR: Findability, Accessibility, Interoper-
ability, and Reusability) [39, 40]. All 1000IBD data that
can be shared without violating patient privacy will be
made available to the scientific community. Researchers
can reuse the 1000IBD data and perform analyses with-
out the need to set up a cohort, collect samples or per-
form expensive sequencing. The sharing and reusing of
the 1000IBD data will drive IBD research forwards.
Additional file
Additional file 1: Table S1. Information_model. This table contains the
information model of the 1000IBD phenotypes. (XLS 98 kb)
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